BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

779 related articles for article (PubMed ID: 27704268)

  • 1. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
    Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
    J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of patients with inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes: A population-based study from the SEER program.
    Li J; Xia Y; Wu Q; Zhu S; Chen C; Yang W; Wei W; Sun S
    Oncotarget; 2017 Jul; 8(30):49370-49379. PubMed ID: 28472761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metastatic behavior and overall survival according to breast cancer subtypes in stage IV inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Strobbe LJA; Bult P; van der Hoeven JJ; Siesling S; de Wilt JHW; Blanken-Peeters CFJM
    Breast Cancer Res; 2019 Oct; 21(1):113. PubMed ID: 31623649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Breast cancer subtypes can be a predictor of pathologic complete response and survival in the neoadjuvant setting for T4 noninflammatory breast cancer.
    Gülben K; Berberoğlu U; Kinaş V; Başkan E
    Acta Chir Belg; 2014; 114(3):153-9. PubMed ID: 25102703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathologic complete response and overall survival in breast cancer subtypes in stage III inflammatory breast cancer.
    van Uden DJP; van Maaren MC; Bult P; Strobbe LJA; van der Hoeven JJM; Blanken-Peeters CFJM; Siesling S; de Wilt JHW
    Breast Cancer Res Treat; 2019 Jul; 176(1):217-226. PubMed ID: 30972613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Locoregional Control According to Breast Cancer Subtype and Response to Neoadjuvant Chemotherapy in Breast Cancer Patients Undergoing Breast-conserving Therapy.
    Swisher SK; Vila J; Tucker SL; Bedrosian I; Shaitelman SF; Litton JK; Smith BD; Caudle AS; Kuerer HM; Mittendorf EA
    Ann Surg Oncol; 2016 Mar; 23(3):749-56. PubMed ID: 26511263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Impact of Residual Disease After Preoperative Systemic Therapy on Clinical Outcomes in Patients with Inflammatory Breast Cancer.
    Nakhlis F; Regan MM; Warren LE; Bellon JR; Hirshfield-Bartek J; Duggan MM; Dominici LS; Golshan M; Jacene HA; Yeh ED; Mullaney EE; Overmoyer B
    Ann Surg Oncol; 2017 Sep; 24(9):2563-2569. PubMed ID: 28560598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer.
    Zhou J; Yan Y; Guo L; Ou H; Hai J; Zhang C; Wu Z; Tang L
    Saudi Med J; 2014 Nov; 35(11):1324-30. PubMed ID: 25399208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy.
    Caudle AS; Yu TK; Tucker SL; Bedrosian I; Litton JK; Gonzalez-Angulo AM; Hoffman K; Meric-Bernstam F; Hunt KK; Buchholz TA; Mittendorf EA
    Breast Cancer Res; 2012 May; 14(3):R83. PubMed ID: 22621334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of Biologic Subtype of Inflammatory Breast Cancer on Response to Neoadjuvant Therapy and Cancer Outcomes.
    Hieken TJ; Murphy BL; Boughey JC; Degnim AC; Glazebrook KN; Hoskin TL
    Clin Breast Cancer; 2018 Aug; 18(4):e501-e506. PubMed ID: 29089281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
    Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
    Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological subtype, treatment response and outcomes in inflammatory breast cancer using data from the National Cancer Database.
    Kupstas AR; Hoskin TL; Day CN; Boughey JC; Habermann EB; Hieken TJ
    Br J Surg; 2020 Jul; 107(8):1033-1041. PubMed ID: 32057107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathologic complete response after neoadjuvant chemotherapy in HER2-overexpressing breast cancer according to hormonal receptor status.
    Tanioka M; Sasaki M; Shimomura A; Fujishima M; Doi M; Matsuura K; Sakuma T; Yoshimura K; Saeki T; Ohara M; Tsurutani J; Watatani M; Takano T; Kawabata H; Mukai H; Naito Y; Hirokaga K; Takao S; Minami H
    Breast; 2014 Aug; 23(4):466-72. PubMed ID: 24742606
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+ Subtypes.
    Murphy BL; Day CN; Hoskin TL; Habermann EB; Boughey JC
    Ann Surg Oncol; 2018 Aug; 25(8):2241-2248. PubMed ID: 29786125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Prognostic Effect of Changes in Tumor Stage and Nodal Status After Neoadjuvant Chemotherapy in Each Primary Breast Cancer Subtype.
    Hayashi N; Takahashi Y; Matsuda N; Tsunoda H; Yoshida A; Suzuki K; Nakamura S; Yamauchi H
    Clin Breast Cancer; 2018 Apr; 18(2):e219-e229. PubMed ID: 29138067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.